Cargando…
Toxicological Characterization of GHB as a Performance-Enhancing Drug
Performance-enhancing drugs (PEDs) are represented by several compounds used to ameliorate the image, the appearance, or an athletic or non-athletic performance. Gamma-hydroxybutyrate (GHB) is an endogenous molecule first used as anesthetic and then marketed as a nutritional supplement with a wide d...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058118/ https://www.ncbi.nlm.nih.gov/pubmed/35509886 http://dx.doi.org/10.3389/fpsyt.2022.846983 |
_version_ | 1784698054002081792 |
---|---|
author | Giorgetti, Arianna Busardò, Francesco Paolo Giorgetti, Raffaele |
author_facet | Giorgetti, Arianna Busardò, Francesco Paolo Giorgetti, Raffaele |
author_sort | Giorgetti, Arianna |
collection | PubMed |
description | Performance-enhancing drugs (PEDs) are represented by several compounds used to ameliorate the image, the appearance, or an athletic or non-athletic performance. Gamma-hydroxybutyrate (GHB) is an endogenous molecule first used as anesthetic and then marketed as a nutritional supplement with a wide diffusion in the bodybuilding community. The aim of the present work is to provide a toxicological characterization of the use of GHB as a PED, including the scientific basis for its use, the patterns of use/abuse, and the health risks arising from its consumption in this peculiar recreative setting. A literature search was performed on multiple databases including experimental studies on humans and animals as well as epidemiological reports and forensic case reports/series. Experimental studies demonstrated that the use of GHB as a PED is motivated by the release of growth hormone and the induction of sleep. However, the panel of desired performance-related effects was much wider in real cases and epidemiological studies. Even though the use of GHB among bodybuilders has decreased, its use to enhance some kind of performance, particularly sexual ones or social-communicative ones, as well as means to increase mood and perceived energy, is still common. |
format | Online Article Text |
id | pubmed-9058118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90581182022-05-03 Toxicological Characterization of GHB as a Performance-Enhancing Drug Giorgetti, Arianna Busardò, Francesco Paolo Giorgetti, Raffaele Front Psychiatry Psychiatry Performance-enhancing drugs (PEDs) are represented by several compounds used to ameliorate the image, the appearance, or an athletic or non-athletic performance. Gamma-hydroxybutyrate (GHB) is an endogenous molecule first used as anesthetic and then marketed as a nutritional supplement with a wide diffusion in the bodybuilding community. The aim of the present work is to provide a toxicological characterization of the use of GHB as a PED, including the scientific basis for its use, the patterns of use/abuse, and the health risks arising from its consumption in this peculiar recreative setting. A literature search was performed on multiple databases including experimental studies on humans and animals as well as epidemiological reports and forensic case reports/series. Experimental studies demonstrated that the use of GHB as a PED is motivated by the release of growth hormone and the induction of sleep. However, the panel of desired performance-related effects was much wider in real cases and epidemiological studies. Even though the use of GHB among bodybuilders has decreased, its use to enhance some kind of performance, particularly sexual ones or social-communicative ones, as well as means to increase mood and perceived energy, is still common. Frontiers Media S.A. 2022-04-18 /pmc/articles/PMC9058118/ /pubmed/35509886 http://dx.doi.org/10.3389/fpsyt.2022.846983 Text en Copyright © 2022 Giorgetti, Busardò and Giorgetti. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Giorgetti, Arianna Busardò, Francesco Paolo Giorgetti, Raffaele Toxicological Characterization of GHB as a Performance-Enhancing Drug |
title | Toxicological Characterization of GHB as a Performance-Enhancing Drug |
title_full | Toxicological Characterization of GHB as a Performance-Enhancing Drug |
title_fullStr | Toxicological Characterization of GHB as a Performance-Enhancing Drug |
title_full_unstemmed | Toxicological Characterization of GHB as a Performance-Enhancing Drug |
title_short | Toxicological Characterization of GHB as a Performance-Enhancing Drug |
title_sort | toxicological characterization of ghb as a performance-enhancing drug |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058118/ https://www.ncbi.nlm.nih.gov/pubmed/35509886 http://dx.doi.org/10.3389/fpsyt.2022.846983 |
work_keys_str_mv | AT giorgettiarianna toxicologicalcharacterizationofghbasaperformanceenhancingdrug AT busardofrancescopaolo toxicologicalcharacterizationofghbasaperformanceenhancingdrug AT giorgettiraffaele toxicologicalcharacterizationofghbasaperformanceenhancingdrug |